cilostazol   

GtoPdb Ligand ID: 7148

Synonyms: OPC-13013 | OPC-21 | Pletal®
cilostazol is an approved drug (FDA (1999))
Compound class: Synthetic organic
Comment: Cilostazol is a quinolinone-derivative phosphodiesterase (PDE) inhibitor.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: cilostazol

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 81.93
Molecular weight 369.22
XLogP 3.48
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES O=C1CCc2c(N1)ccc(c2)OCCCCc1nnnn1C1CCCCC1
Isomeric SMILES O=C1CCc2c(N1)ccc(c2)OCCCCc1nnnn1C1CCCCC1
InChI InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
InChI Key RRGUKTPIGVIEKM-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Used to improve circulatory defecit in the legs which causes intermittent claudication.
Mechanism Of Action and Pharmacodynamic Effects
Cilostazol inhibits phosphodiesterase 3A. This results in increased cAMP levels in platelets and blood vessels and leads to inhibition of platelet aggregation and vasodilation, thereby improving circulation.
External links